




Curriculum Vitae

** CV must be written in English*

Personal Information	
Title (i.e. Pf., Dr., etc.)	Professor and Chair
Name (First Name/ Middle Name /Last Name)	Shinichiro Shinzaki
Degree (i.e. MD, MSc, PhD, etc.)	M.D., Ph.D.
Country	Japan
Affiliation	Department of Gastroenterology, Hyogo Medical University School of Medicine
E-mail	sh-shinzaki@hyo-med.ac.jp
	
Educational Background	
Osaka University Medical School	M.D. 1998 Medicine
Osaka University Graduate School of Medicine	Ph.D. 2008 Gastroenterology
Professional Career	
1998-1999 Clinical Training Course at Osaka University Hospital, Osaka, Japan	
1999-2002 Junior & Senior Resident at Dept. of Gastroenterology, Osaka Koseinenkin Hospital, Osaka, Japan	
2002-2004 Medical Staff at Dept. of Gastroenterology, Osaka Rosai Hospital, Osaka, Japan	
2004-2008 Graduate Student at Dept. of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan	
2008-2009 Clinical fellow at Dept. of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan	
2009-2011 Assistant professor, Dept. of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Suita, Japan	
2011 Visiting assistant professor, Center for Gastrointestinal Biology and Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA	
2011-2012 Assistant professor, Oncology Center, Osaka University Hospital, Suita, Japan	
2012-2017 Assistant professor, Dept. of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan	
2017-2022 Associate professor (Lecturer), Dept. of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan	
2022-present Professor & Chair, Department of Gastroenterology, Hyogo Medical University School of Medicine, Nishinomiya, Japan Director, Division of Gastrointestinal Diseases, Hyogo Medical University Hospital, Nishinomiya, Japan Director, IBD center, Hyogo Medical University Hospital, Nishinomiya, Japan	



Research Field

Gastroenterology
Inflammatory Bowel Disease
Clinical Trials
Mucosal Immunology
Glycobiology

Main Scientific Publications

Main Achievements (10 max)

1. Sato T, Uchino M, Takeuchi J, Fujihira Y, Shimizu K, Yokoyama K, Yagi S, Kaku K, Takashima Y, Ikenouchi M, Kojima K, Kawai M, Nagase K, Kamikozuru K, Yokoyama Y, Takagawa T, Ikeuchi H, Watanabe K, **Shinzaki S**. Short-term clinical evaluation of teduglutide for patients with Crohn's disease on home parenteral support for postoperative short bowel syndrome with intestinal failure. *Clin Nutr*. 2023 May;42(5):722-731.
2. Otake-Kasamoto Y, Kayama H, Kishikawa T, **Shinzaki S**, Tashiro T, Amano T, Tani M, Yoshihara T, Li B, Tani H, Liu L, Hayashi A, Okuzaki D, Motooka D, Nakamura S, Okada Y, Iijima H, Takeda K, Takehara T. Lysophosphatidylserines derived from microbiota in Crohn's disease elicit pathological Th1 response. *J Exp Med*. 2022 Jul 4;219(7):e20211291.
3. **Shinzaki S**, Matsuoka K, Tanaka H, Takeshima F, Kato S, Torisu T, Ohta Y, Watanabe K, Nakamura S, Yoshimura N, Kobayashi T, Shiotani A, Hirai F, Hiraoka S, Watanabe M, Matsuura M, Nishimoto S, Mizuno S, Iijima H, Takehara T, Naka T, Kanai T, Matsumoto T. Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study. *J Gastroenterol*. 2021 Jun; 56(6):560-569.
4. Yoshihara T*, **Shinzaki S***, Kawai S, Fujii H, Iwatani S, Yamaguchi T, Araki M, Hiyama S, Inoue T, Hayashi Y, Watabe K, Iijima H, Takehara T. Tissue drug concentrations of anti-tumor necrosis factor agents are associated with the long-term outcome of patients with Crohn's disease. *Inflamm Bowel Dis*. 2017 Dec; 23(12):2172-2179.
5. **Shinzaki S**, Matsuoka K, Iijima H, Mizuno S, Serada S, Fujimoto M, Arai N, Koyama N, Morii E, Watanabe M, Hibi T, Kanai T, Takehara T, Naka T. Leucine-rich alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis. *J Crohns Colitis*. 2017 Jan;11(1):84-91.
6. Fujii H*, **Shinzaki S***, Iijima H*, Wakamatsu K, Iwamoto C, Sobajima T, Kuwahara R, Hiyama S, Hayashi Y, Takamatsu S, Uozumi N, Kamada Y, Tsujii M, Taniguchi N, Takehara T, Miyoshi E. Core Fucosylation on T cells, Required for Activation of T-cell Receptor Signaling and Induction of Colitis in Mice, is Increased in Patients with Inflammatory Bowel Disease. *Gastroenterology*. 2016 Jun;150(7): 1620-32.
7. **Shinzaki S**, Ishii M, Fujii H, Iijima H, Wakamatsu K, Kawai S, Shiraishi E, Hiyama S, Inoue T, Hayashi Y, Kuwahara R, Takamatsu S, Kamada Y, Morii E, Tsujii M, Takehara T, Miyoshi E. N-Acetylglucosaminyltransferase V exacerbates murine colitis with macrophage dysfunction and enhances colitic tumorigenesis. *J Gastroenterol*. 2016 Apr;51(4):357-69
8. **Shinzaki S**, Iijima H, Fujii H, Kuroki E, Tatsunaka N, Inoue T, Nakajima S, Egawa S, Kanto T, Tsujii M, Morii E, Takeishi S, Asano M, Takehara T, Hayashi N, Miyoshi E. Altered oligosaccharide structures reduce colitis induction in mice defective in β -1,4-galactosyltransferase. *Gastroenterology*. 2012 May;142(5):1172-82.
9. Serada S, Fujimoto M, Ogata A, Terabe F, Hirano T, Iijima H, **Shinzaki S**, Nishikawa T, Ohkawara T, Iwahori K, Ohguro N, Kishimoto T, Naka T. iTRAQ-based proteomic identification of leucine rich alpha 2 glycoprotein (LRG) as a novel inflammatory biomarker in autoimmune diseases. *Ann Rheum Dis*. 2010. 69(4) 770-774.
10. **Shinzaki S**, Iijima H, Nakagawa T, Egawa S, Nakajima S, Ishii S, Irie T, Kakiuchi Y, Nishida T, Yasumaru M, Kanto T, Tsujii M, Tsuji S, Mizushima T, Yoshihara H, Kondo A, Miyoshi E, Hayashi N. IgG oligosaccharide alterations are a novel diagnostic marker for disease activity and the clinical course of inflammatory bowel disease. *Am J Gastroenterol*. 2008 May;103(5):1173-81.

- Please note that the above information will be used for the introduction of speakers for the IMKASID 2025 website and announcements. Also, it will be provided to the session chairpersons before your lecture.

- Please complete this form (no more than 2 pages) and return it to the IMKASID 2025 secretariat by email, info@imkasid.kr.